EE03028B1 - Sulfoonamiidid, nende kasutamine, ravimid ja valmistamise meetod - Google Patents
Sulfoonamiidid, nende kasutamine, ravimid ja valmistamise meetodInfo
- Publication number
- EE03028B1 EE03028B1 EE9400322A EE9400322A EE03028B1 EE 03028 B1 EE03028 B1 EE 03028B1 EE 9400322 A EE9400322 A EE 9400322A EE 9400322 A EE9400322 A EE 9400322A EE 03028 B1 EE03028 B1 EE 03028B1
- Authority
- EE
- Estonia
- Prior art keywords
- sulfonamides
- drugs
- preparation
- vasopasms
- ischemia
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/69—Benzenesulfonamido-pyrimidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Lubricants (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Bipolar Transistors (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Glass Compositions (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH176091 | 1991-06-13 | ||
CH151692 | 1992-05-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
EE03028B1 true EE03028B1 (et) | 1997-08-15 |
Family
ID=25687870
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EE9400322A EE03028B1 (et) | 1991-06-13 | 1994-11-23 | Sulfoonamiidid, nende kasutamine, ravimid ja valmistamise meetod |
Country Status (34)
Country | Link |
---|---|
US (1) | US5292740A (el) |
EP (1) | EP0526708B1 (el) |
JP (1) | JPH0730042B2 (el) |
KR (1) | KR100235507B1 (el) |
AT (1) | ATE197044T1 (el) |
AU (1) | AU653604B2 (el) |
BG (1) | BG60831B2 (el) |
BR (1) | BR9202219A (el) |
CA (1) | CA2071193C (el) |
CY (2) | CY2306B1 (el) |
CZ (1) | CZ281434B6 (el) |
DE (2) | DE59209872D1 (el) |
DK (1) | DK0526708T3 (el) |
DZ (1) | DZ1587A1 (el) |
EE (1) | EE03028B1 (el) |
ES (1) | ES2152222T4 (el) |
FI (1) | FI112216B (el) |
GR (1) | GR3035162T3 (el) |
HU (2) | HU221203B1 (el) |
IE (1) | IE921920A1 (el) |
IL (1) | IL102138A (el) |
IS (1) | IS2054B (el) |
LU (2) | LU90976I2 (el) |
MX (1) | MX9202747A (el) |
NL (1) | NL300097I1 (el) |
NO (2) | NO303826B1 (el) |
NZ (1) | NZ243074A (el) |
PT (1) | PT526708E (el) |
RO (1) | RO111268B (el) |
RU (1) | RU2086544C1 (el) |
SG (1) | SG54209A1 (el) |
SK (1) | SK279006B6 (el) |
TW (1) | TW222625B (el) |
ZA (1) | ZA924126B (el) |
Families Citing this family (187)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5591761A (en) * | 1993-05-20 | 1997-01-07 | Texas Biotechnology Corporation | Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
US5514691A (en) * | 1993-05-20 | 1996-05-07 | Immunopharmaceutics, Inc. | N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin |
US5571821A (en) * | 1993-05-20 | 1996-11-05 | Texas Biotechnology Corporation | Sulfonamides and derivatives thereof that modulate the activity of endothelin |
US5594021A (en) * | 1993-05-20 | 1997-01-14 | Texas Biotechnology Corporation | Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin |
US5962490A (en) | 1987-09-25 | 1999-10-05 | Texas Biotechnology Corporation | Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
ES2070332T3 (es) * | 1989-08-30 | 1995-06-01 | Irwin Fox | Soporte de oxido desechable para eliminacion de sulfuro de hidrogeno. |
US5736509A (en) * | 1990-12-14 | 1998-04-07 | Texas Biotechnology Corporation | Cyclic peptide surface feature mimics of endothelin |
TW224462B (el) * | 1992-02-24 | 1994-06-01 | Squibb & Sons Inc | |
US5378715A (en) * | 1992-02-24 | 1995-01-03 | Bristol-Myers Squibb Co. | Sulfonamide endothelin antagonists |
NZ247440A (en) * | 1992-05-06 | 1995-04-27 | Squibb & Sons Inc | Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof |
US5514696A (en) * | 1992-05-06 | 1996-05-07 | Bristol-Myers Squibb Co. | Phenyl sulfonamide endothelin antagonists |
US5420123A (en) * | 1992-12-21 | 1995-05-30 | Bristol-Myers Squibb Company | Dibenzodiazepine endothelin antagonists |
US5352800A (en) * | 1993-03-11 | 1994-10-04 | Merck & Co., Inc. | Process for the production of a novel endothelin antagonist |
US5401745A (en) * | 1993-03-19 | 1995-03-28 | Merck & Co., Inc. | Quinazolinones substituted with phenoxyphenylacetic acid derivatives |
US5767310A (en) * | 1993-03-19 | 1998-06-16 | Merck & Co., Inc. | Phenoxyphenylacetic acid derivatives |
US5420133A (en) * | 1993-03-19 | 1995-05-30 | Merck & Co., Inc. | Quinazolinones substituted with phenoxyphenylacetic acid derivatives |
US5374638A (en) * | 1993-03-19 | 1994-12-20 | Merck & Co., Inc. | Six membered ring fused imidazoles substituted with phenoxyphenylacetic acid derivatives used to treat asthma |
US5334598A (en) * | 1993-03-19 | 1994-08-02 | Merck & Co., Inc. | Six-membered ring fused imidazoles substituted with phenoxyphenylacetic acid derivatives |
CA2121724A1 (en) * | 1993-04-21 | 1994-10-22 | Toshifumi Watanabe | Methods and compositions for the prophylactic and/or therapeutic treatment of organ hypofunction |
US6613804B2 (en) | 1993-05-20 | 2003-09-02 | Encysive Pharmaceuticals, Inc. | Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin |
US6030991A (en) * | 1993-05-20 | 2000-02-29 | Texas Biotechnology Corp. | Benzenesulfonamides and the use thereof to modulate the activity of endothelin |
US6376523B1 (en) | 1994-05-20 | 2002-04-23 | Texas Biotechnology Corporation | Benzenesulfonamides and the use thereof to modulate the activity of endothelin |
US6342610B2 (en) | 1993-05-20 | 2002-01-29 | Texas Biotechnology Corp. | N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
US6541498B2 (en) | 1993-05-20 | 2003-04-01 | Texas Biotechnology | Benzenesulfonamides and the use thereof to modulate the activity of endothelin |
US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
TW394761B (en) * | 1993-06-28 | 2000-06-21 | Hoffmann La Roche | Novel Sulfonylamino Pyrimidines |
DK0634175T3 (da) * | 1993-07-15 | 2001-04-30 | Hoffmann La Roche | Farmaceutisk kombination, der indeholder en hæmmer af renin-angiotensin-systemet og en endothelin-antagonist |
US5686478A (en) * | 1993-07-20 | 1997-11-11 | Merck & Co. Inc. | Endothelin antagonists |
US6140325A (en) * | 1993-08-19 | 2000-10-31 | Takeda Chemical Industries, Ltd. | Thienopyrimidine derivatives, their production and use |
US5965732A (en) * | 1993-08-30 | 1999-10-12 | Bristol-Myers Squibb Co. | Sulfonamide endothelin antagonists |
CA2173875A1 (en) * | 1993-11-01 | 1995-05-11 | Hideyuki Saika | Endothelin receptor antagonists |
IL111959A (en) * | 1993-12-17 | 2000-07-16 | Tanabe Seiyaku Co | N-(polysubstituted pyrimidin-4-yl) benzenesulfonamide derivatives their preparation and pharmaceutical compositions containing them |
GB9504854D0 (en) * | 1994-03-31 | 1995-04-26 | Zeneca Ltd | Nitrogen derivatives |
GB9409618D0 (en) * | 1994-05-13 | 1994-07-06 | Zeneca Ltd | Pyridine derivatives |
US5612359A (en) * | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
US5559135A (en) * | 1994-09-14 | 1996-09-24 | Merck & Co., Inc. | Endothelin antagonists bearing pyridyl amides |
US5538991A (en) * | 1994-09-14 | 1996-07-23 | Merck & Co., Inc. | Endothelin antagonists bearing 5-membered heterocyclic amides |
US6268369B1 (en) | 1994-11-16 | 2001-07-31 | Synaptic Pharmaceutical Corporation | 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines |
KR970706823A (ko) | 1994-11-16 | 1997-12-01 | 멀닉스 캐슬린 피. | 디히드로피리미딘과 그 사용법(dihydropyrimidines and uses thereof) |
US5837708A (en) * | 1994-11-25 | 1998-11-17 | Hoffmann-La Roche Inc. | Sulphonamides |
WO1996016963A1 (de) * | 1994-11-25 | 1996-06-06 | F. Hoffmann-La Roche Ag | Sulfonamide und deren verwendung als heilmittel |
CA2162630C (en) * | 1994-11-25 | 2007-05-01 | Volker Breu | Sulfonamides |
CN1064965C (zh) * | 1994-11-25 | 2001-04-25 | 弗·哈夫曼-拉罗切有限公司 | 新的磺酰胺类化合物及其作为药物的用途 |
TW313568B (el) * | 1994-12-20 | 1997-08-21 | Hoffmann La Roche | |
NZ297774A (en) * | 1994-12-20 | 1998-10-28 | Hoffmann La Roche | Aryl and heteroaryl sulphonamide derivatives; preparation and medicaments |
ATE238285T1 (de) * | 1994-12-28 | 2003-05-15 | Kowa Co | Pyrimidin-derivate |
US5760038A (en) * | 1995-02-06 | 1998-06-02 | Bristol-Myers Squibb Company | Substituted biphenyl sulfonamide endothelin antagonists |
US5780473A (en) * | 1995-02-06 | 1998-07-14 | Bristol-Myers Squibb Company | Substituted biphenyl sulfonamide endothelin antagonists |
US5573762A (en) * | 1995-04-24 | 1996-11-12 | Genentech, Inc. | Use of leukemia inhibitory factor specific antibodies and endothelin antagonists for treatment of cardiac hypertrophy |
US5739333A (en) * | 1995-05-16 | 1998-04-14 | Tanabe Seiyaku Co., Ltd. | Sulfonamide derivative and process for preparing the same |
UA58494C2 (uk) | 1995-06-07 | 2003-08-15 | Зенека Лімітед | Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну |
GB9512697D0 (en) * | 1995-06-22 | 1995-08-23 | Zeneca Ltd | Heterocyclic compounds |
DE19527568A1 (de) * | 1995-07-28 | 1997-01-30 | Merck Patent Gmbh | Endothelin-Rezeptor-Antagonisten |
US5846990A (en) * | 1995-07-24 | 1998-12-08 | Bristol-Myers Squibb Co. | Substituted biphenyl isoxazole sulfonamides |
DE19528418A1 (de) * | 1995-08-02 | 1997-02-06 | Merck Patent Gmbh | Endothelin-Rezeptor-Antagonisten |
DE19530032A1 (de) * | 1995-08-16 | 1997-02-20 | Merck Patent Gmbh | Endothelin-Rezeptor-Antagonisten |
JPH09124620A (ja) | 1995-10-11 | 1997-05-13 | Bristol Myers Squibb Co | 置換ビフェニルスルホンアミドエンドセリン拮抗剤 |
CZ260596A3 (en) * | 1995-10-12 | 1997-12-17 | Hoffmann La Roche | Sulfonamide derivative, process of its preparation and pharmaceutical composition containing thereof |
US6228861B1 (en) | 1995-11-16 | 2001-05-08 | Synaptic Pharmaceutical Corporation | Dihydropyrimidines and uses thereof |
CN1102580C (zh) * | 1995-12-20 | 2003-03-05 | 山之内制药株式会社 | 芳基乙烯基磺酰胺衍生物及其医药组合物 |
US5977117A (en) * | 1996-01-05 | 1999-11-02 | Texas Biotechnology Corporation | Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin |
US5856507A (en) * | 1997-01-21 | 1999-01-05 | Bristol-Myers Squibb Co. | Methods for the preparation of biphenyl isoxazole sulfonamides |
NZ330464A (en) | 1996-02-20 | 2000-04-28 | Bristol Myers Squibb Co | Methods for the preparation of biphenyl isoxazole sulfonamides |
US5958905A (en) * | 1996-03-26 | 1999-09-28 | Texas Biotechnology Corporation | Phosphoramidates, phosphinic amides and related compounds and the use thereof to modulate the activity of endothelin |
US5939446A (en) * | 1996-04-09 | 1999-08-17 | Bristol-Myers Squibb Co. | Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists |
US5804585A (en) | 1996-04-15 | 1998-09-08 | Texas Biotechnology Corporation | Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin |
US6245773B1 (en) | 1996-05-16 | 2001-06-12 | Synaptic Pharmaceutical Corporation | 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines |
US6172066B1 (en) | 1996-05-16 | 2001-01-09 | Synaptic Pharmaceutical Corporation | Dihydropyrimidines and uses thereof |
AU711936B2 (en) * | 1996-08-09 | 1999-10-28 | Banyu Pharmaceutical Co., Ltd. | Stereoselective deoxygenation reaction |
AU4196697A (en) * | 1996-09-16 | 1998-04-14 | Dalhousie University | Use of igf-i for the treatment of polycystic kidney disease and related indications |
US5883254A (en) * | 1996-11-08 | 1999-03-16 | Hoffmann-La Roche Inc. | Process for making pyrimidine derivatives |
DE19653024A1 (de) * | 1996-12-19 | 1998-06-25 | Merck Patent Gmbh | Endothelin-Rezeptor-Antagonisten |
US5998625A (en) * | 1997-01-14 | 1999-12-07 | Merck & Co., Inc. | Asymmetric conjugate addition reaction using a chiral additive |
HRP980001A2 (en) * | 1997-01-14 | 1998-10-31 | Feng Xu | Asymmetric conjugate addition reaction using a chiral additive |
AU6187898A (en) * | 1997-01-30 | 1998-08-25 | Bristol-Myers Squibb Company | Method for preventing or treating low renin hypertension by administering an endothelin antagonist |
TW536540B (en) * | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
TR200101905T2 (tr) | 1997-04-28 | 2002-06-21 | Texas Biotechnology Corporation | Endotelin ile ilgili hastalıkların tedavisinde kullanılan sülfanoamidler. |
US5783705A (en) | 1997-04-28 | 1998-07-21 | Texas Biotechnology Corporation | Process of preparing alkali metal salys of hydrophobic sulfonamides |
US6022972A (en) | 1997-08-08 | 2000-02-08 | Merck & Co., Inc. | Pyridine propanoic acid derivatives |
US6410554B1 (en) | 1998-03-23 | 2002-06-25 | Merck & Co., Inc. | Combination therapy for the treatment of benign prostatic hyperplasia |
US6136971A (en) * | 1998-07-17 | 2000-10-24 | Roche Colorado Corporation | Preparation of sulfonamides |
US6274585B1 (en) | 1998-12-23 | 2001-08-14 | Synaptic Pharmaceutical Corporation | Dihydropyrimidines and uses thereof |
US6680323B2 (en) | 1998-12-23 | 2004-01-20 | Synaptic Pharmaceutical Corporation | Dihydropyrimidines and uses thereof |
KR20020004974A (ko) | 1999-03-19 | 2002-01-16 | 스티븐 비. 데이비스 | 비페닐 이속사졸 술폰아미드의 제조방법 |
DE19916719A1 (de) * | 1999-04-13 | 2000-10-19 | Basf Ag | Neue ECE-Inhibitoren, ihre Herstellung und Verwendung |
US7566452B1 (en) | 1999-05-04 | 2009-07-28 | New York University | Cancer treatment with endothelin receptor antagonists |
IL149529A0 (en) * | 1999-12-22 | 2002-11-10 | Actelion Pharmaceuticals Ltd | Butyne diol derivatives |
US6720322B2 (en) * | 1999-12-22 | 2004-04-13 | Actelion Pharamceuticals Ltd. | Butyne diol derivatives |
AU2464301A (en) | 1999-12-31 | 2001-07-16 | Encysive Pharmaceuticals Inc. | Sulfonamides and derivatives thereof that modulate the activity of endothelin |
PT1254121E (pt) * | 2000-01-25 | 2006-06-30 | Hoffmann La Roche | Preparacao de sulfonamidas |
US6521632B2 (en) | 2000-02-11 | 2003-02-18 | Oy Juvantia Pharma Ltd | Method for the treatment or prevention of a disease mediated by the alpha-2B-adrenoceptor |
YU59102A (sh) * | 2000-02-11 | 2005-11-28 | Oy Juvantia Pharma Ltd. | JEDINJENJA KORISNA ZA LEČENJE ILI PREVENCIJU OBOLJENJA U KOJEM UČESTVUJE ALFA-2β-ADRENOCEPTOR |
US6720324B2 (en) * | 2000-07-05 | 2004-04-13 | Synaptic Pharmaceutical Corporation | Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof |
MY140724A (en) * | 2000-07-21 | 2010-01-15 | Actelion Pharmaceuticals Ltd | Novel arylethene-sulfonamides |
US6670362B2 (en) | 2000-09-20 | 2003-12-30 | Pfizer Inc. | Pyridazine endothelin antagonists |
US6639082B2 (en) | 2000-10-17 | 2003-10-28 | Bristol-Myers Squibb Company | Methods for the preparation of biphenyl isoxazole sulfonamides |
US8168616B1 (en) * | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
EP1693372A1 (en) | 2000-12-18 | 2006-08-23 | Actelion Pharmaceuticals Ltd. | Novel Sulfamides and their use as endothelin receptor antagonists |
FI116940B (fi) | 2001-07-20 | 2006-04-13 | Juvantia Pharma Ltd Oy | Alfa-2B-adrenoseptorivälitteisen sairauden hoitoon tai ehkäisyyn käyttökelpoiset yhdisteet |
IL159511A0 (en) * | 2001-07-20 | 2004-06-01 | Juvantia Pharma Ltd Oy | Compounds useful for treatment or prevention of disease mediated by alpha-2b-adrenoceptor |
FR2831446B1 (fr) * | 2001-10-26 | 2004-03-05 | Sanofi Synthelabo | Utilisation de l'irbesartan pour la preparation de medicaments utiles pour la prevention ou le traitement de l'hypertension pulmonaire |
EP1490090A4 (en) | 2002-02-22 | 2006-09-20 | New River Pharmaceuticals Inc | SYSTEMS FOR DELIVERING ACTIVE AGENTS AND METHODS FOR PROTECTING AND DELIVERING ACTIVE AGENTS |
US7238717B2 (en) | 2002-05-24 | 2007-07-03 | Millennium Pharmaceuticals, Inc. | CCR9 inhibitors and methods of use thereof |
GB0219660D0 (en) | 2002-08-23 | 2002-10-02 | Astrazeneca Ab | Therapeutic use |
CA2412856A1 (en) * | 2002-11-27 | 2004-05-27 | Frederic Bodin | Pharmaceutical composition for the treatment of pulmonary arterial hypertension |
BR0316724A (pt) | 2002-12-02 | 2005-10-18 | Actelion Pharmaceuticals Ltd | Compostos, uso de um ou mais compostos, e, processo para a fabricação de composições farmacêuticas |
US20050101608A1 (en) * | 2003-09-24 | 2005-05-12 | Santel Donald J. | Iloprost in combination therapies for the treatment of pulmonary arterial hypertension |
GB0327839D0 (en) | 2003-12-01 | 2003-12-31 | Novartis Ag | Organic compounds |
GB0403744D0 (en) | 2004-02-20 | 2004-03-24 | Astrazeneca Ab | Chemical process |
SG153831A1 (en) | 2004-03-17 | 2009-07-29 | Novartis Ag | Use of renin inhibitors in therapy |
EP1796653A2 (en) * | 2004-07-26 | 2007-06-20 | Actelion Pharmaceuticals Ltd. | Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation |
TW200628467A (en) | 2004-11-11 | 2006-08-16 | Actelion Pharmaceuticals Ltd | Novel sulfamides |
CA2607098C (en) * | 2005-05-17 | 2012-04-10 | Actelion Pharmaceuticals Ltd | Dispersible bosentan tablet |
GT200600381A (es) | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
WO2007031933A2 (en) * | 2005-09-12 | 2007-03-22 | Actelion Pharmaceuticals Ltd | Stable pharmaceutical composition comprising a pyrimidine-sulfamide |
EP1951253A2 (en) * | 2005-10-26 | 2008-08-06 | Cotherix, Inc. | Fasudil in combination therapies for the treatment of pulmonary arterial hypertension |
EP2351569B1 (en) | 2005-10-26 | 2012-08-22 | Asahi Kasei Pharma Corporation | Fasudil in combination therapies for the treatment of pulmonary arterial hypertension |
EP1996162A2 (en) * | 2006-03-13 | 2008-12-03 | Encysive Pharmaceuticals, Inc | Methods and compositions for treatment of diastolic heart failure |
AU2007225207A1 (en) * | 2006-03-13 | 2007-09-20 | Encysive Pharmaceuticals, Inc. | Formulations of sitaxsentan sodium |
BRPI0709950A2 (pt) * | 2006-04-13 | 2011-08-02 | Actelion Pharmaceuticals Ltd | uso de bosentan na preparação de um medicamento para o tratamento de fibrose pulmonar idiopática em estágio precoce e uso de antagonista do receptor endotelin |
US20080026061A1 (en) * | 2006-06-22 | 2008-01-31 | Reichwein John F | Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide |
PL2049517T3 (pl) | 2006-07-20 | 2014-06-30 | Novartis Ag | Pochodne amino-piperydyny jako inhibitory CETP |
AR062501A1 (es) * | 2006-08-29 | 2008-11-12 | Actelion Pharmaceuticals Ltd | Composiciones terapeuticas |
US8080549B2 (en) * | 2007-01-12 | 2011-12-20 | Concert Pharmaceuticals, Inc. | Endothelin receptor antagonists |
US8071596B2 (en) | 2007-01-12 | 2011-12-06 | Concert Pharmaceuticals, Inc. | Endothelin receptor antagonists |
EP2132199A1 (en) * | 2007-04-02 | 2009-12-16 | Auspex Pharmaceuticals Inc. | Substituted pyrimidines |
US8288401B2 (en) * | 2007-05-08 | 2012-10-16 | Generics [Uk] Limited | Polymorphic forms |
US8664390B2 (en) | 2007-06-29 | 2014-03-04 | Generics (Uk) Limited | Process for the introduction of hydroxyethoxy side chain in bosentan |
MX2010001837A (es) | 2007-08-17 | 2010-03-10 | Actelion Pharmaceuticals Ltd | Derivados de 4-pirimidinasulfamida. |
US20090069351A1 (en) * | 2007-09-09 | 2009-03-12 | Protia, Llc | Deuterium-enriched bosentan |
US20110014291A1 (en) * | 2007-10-11 | 2011-01-20 | Actavis Group Ptc Ehf | Novel Polymorphs of Bosentan |
CN101939303B (zh) * | 2007-10-24 | 2014-06-11 | 基因里克斯(英国)有限公司 | 波生坦的晶型 |
PL2207775T3 (pl) | 2007-11-05 | 2012-08-31 | Novartis Ag | Pochodne 4-benzyloamino-1-karboksyacylo-piperydyny jako inhibitory CETP użyteczne do leczenia chorób, takich jak hiperlipidemia lub stwardnienie tętnic |
ES2375527T3 (es) | 2007-12-03 | 2012-03-01 | Novartis Ag | Derivados 1,2-disustituidos-4-bencilamino-pirrolidina como inhibidores cetp útiles para el tratamiento de enfermedades tales como hiperlipidemia o arteriosclerosis. |
EP2072503B1 (en) * | 2007-12-18 | 2011-10-26 | Dipharma Francis S.r.l. | Process for the preparation of bosentan |
JP5535082B2 (ja) * | 2008-01-01 | 2014-07-02 | シプラ・リミテッド | ボセンタン、その多形形態及びその塩の合成方法 |
WO2009095933A2 (en) * | 2008-01-10 | 2009-08-06 | Msn Laboratories Limited | Improved and novel process for the preparation of bosentan |
EP2240469A2 (en) * | 2008-01-24 | 2010-10-20 | Actavis Group PTC EHF | Substantially pure and a stable crystalline form of bosentan |
WO2009098517A1 (en) * | 2008-02-08 | 2009-08-13 | Generics [Uk] Limited | Process for preparing bosentan |
CN101279948B (zh) * | 2008-03-14 | 2010-08-11 | 苏州博鸿化工技术有限公司 | 4,6-二氯-5-(2-甲氧基苯氧基)-2,2'-二嘧啶的合成方法 |
EP2294056A1 (en) * | 2008-05-23 | 2011-03-16 | Synthon B.V. | Bosentan salts |
EP2307019A1 (en) * | 2008-06-03 | 2011-04-13 | Fresenius Medical Care Deutschland GmbH | Pharmaceutical compositions comprising gamma secretase modulators |
WO2010012637A1 (en) * | 2008-08-01 | 2010-02-04 | Inke, S.A. | Process for the preparation of bosentan |
WO2010015623A1 (en) * | 2008-08-05 | 2010-02-11 | Farmaprojects, S. A. | Process for the preparation of endothelin receptor antagonists |
EP2331513A1 (en) * | 2008-08-12 | 2011-06-15 | Cadila Healthcare Limited | Process for preparation of bosentan |
US8975402B2 (en) | 2008-11-03 | 2015-03-10 | Generics [Uk] Limited | HPLC method for the analysis of bosetan and related substances and use of these substances as reference standards and markers |
IT1393136B1 (it) * | 2009-03-11 | 2012-04-11 | Sifa Vitor S R L | Procedimento per la preparazione del bosentan |
US20100256371A1 (en) * | 2009-04-02 | 2010-10-07 | Glenmark | Processes for the preparation of bosentan and its intermediates thereof |
US20120136015A1 (en) | 2009-04-13 | 2012-05-31 | Sandoz Ag | Process for preparation of endothelial receptor antagonist (bosentan) |
BRPI1012852A2 (pt) | 2009-05-15 | 2018-06-19 | Novartis Ag | derivados de benzoxazolona como inibidores da sintase de aldoesterona |
EP2429995B1 (en) | 2009-05-15 | 2014-01-22 | Novartis AG | Aryl pyridine as aldosterone synthase inhibitors |
MX2011012627A (es) | 2009-05-28 | 2011-12-14 | Novartis Ag | Derivados aminobutiricos sustituidos como inhibidores de nepralisina. |
NZ596304A (en) | 2009-05-28 | 2014-01-31 | Novartis Ag | Substituted aminopropionic derivatives as neprilysin inhibitors |
WO2011024056A2 (en) | 2009-08-27 | 2011-03-03 | Aurobindo Pharma Limited | An improved process for the preparation of bosentan |
CA2781541A1 (en) | 2009-11-12 | 2011-05-19 | Ranbaxy Laboratories Limited | Crystalline forms of bosentan salt and processes for their preparation |
CN102712589B (zh) | 2009-11-17 | 2015-05-13 | 诺华股份有限公司 | 作为醛固酮合酶抑制剂的芳基-吡啶衍生物 |
JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
JP5575913B2 (ja) | 2009-11-30 | 2014-08-20 | ノバルティス アーゲー | アルドステロン合成酵素阻害剤としてのイミダゾール誘導体 |
US20120283190A1 (en) | 2009-12-09 | 2012-11-08 | Institut National de la Santé et de la Recherche Medicale (INSERM) | Endothelin inhibitors for the treatment of rapidly progressive glomerulonephritis |
EP2368884A1 (en) | 2010-03-25 | 2011-09-28 | Laboratorios Lesvi, S.L. | Process for the preparation of bosentan |
JP5850576B2 (ja) * | 2010-07-06 | 2016-02-03 | 富士化学工業株式会社 | ボセンタン固体分散体 |
EP2603497B1 (en) | 2010-08-11 | 2018-08-08 | Megafine Pharma (P) Ltd. | A novel process for preparation of bosentan |
WO2012041764A1 (en) | 2010-10-01 | 2012-04-05 | Zach System S.P.A. | Process for preparing bosentan monohydrate and its intermediates |
WO2012056468A1 (en) | 2010-10-13 | 2012-05-03 | Matrix Laboratories Ltd | A process for the preparation of bosentan |
US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
US8877815B2 (en) | 2010-11-16 | 2014-11-04 | Novartis Ag | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP |
WO2012073135A1 (en) | 2010-12-03 | 2012-06-07 | Alembic Pharmaceuticals Limited | An improved process for preparing bosentan |
ES2386173B1 (es) * | 2011-01-13 | 2013-06-25 | Urquima, S.A. | Proceso de preparación de un antagonista del receptor de la endotelina |
WO2012139736A1 (en) | 2011-04-11 | 2012-10-18 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Pharmaceutical composition comprising bosentan |
CN102796050B (zh) * | 2011-05-23 | 2014-07-23 | 昂科生物医学技术(苏州)有限公司 | 一种Cdc42抑制剂及其应用 |
WO2013098577A1 (en) | 2011-12-31 | 2013-07-04 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Pharmaceutical compositions of bosentan |
US20130245259A1 (en) | 2012-03-16 | 2013-09-19 | Natco Pharma Limited | Process for the preparation of bosentan monohydrate |
ITMI20120701A1 (it) | 2012-04-27 | 2013-10-28 | Dipharma Francis Srl | Procedimento per la purificazione di un composto benzensolfonammidico |
US20140377346A1 (en) | 2012-05-11 | 2014-12-25 | Hanall Biopharma Co., Ltd. | Bosentan controlled release oral preparation |
JP2015521594A (ja) | 2012-06-12 | 2015-07-30 | カディラ ファーマシューティカルズ リミテッド | ボセンタンの製造方法 |
US9296705B2 (en) | 2012-08-31 | 2016-03-29 | Davuluri Ramamohan Rao | 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2(2-pyrimidinyl)-pyrimidine-4-yl)-benzen esulfonamide sodium |
UY35144A (es) | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
KR102004422B1 (ko) | 2012-12-20 | 2019-07-26 | 제일약품주식회사 | 보센탄 일수화물의 제조방법, 이에 사용되는 신규 중간체 및 이의 제조방법 |
KR20150119109A (ko) | 2013-02-14 | 2015-10-23 | 노파르티스 아게 | Nep (중성 엔도펩티다제) 억제제로서의 치환된 비스페닐 부타노익 포스폰산 유도체 |
PE20160991A1 (es) | 2013-07-25 | 2016-10-15 | Novartis Ag | Bioconjugados de polipeptidos de apelina sintetica |
CA2918074A1 (en) | 2013-07-25 | 2015-01-29 | Novartis Ag | Cyclic polypeptides for the treatment of heart failure |
CN103554037B (zh) * | 2013-11-08 | 2015-03-18 | 南京靖龙药物研发有限公司 | 一种波生坦代谢物羟基波生坦的制备方法 |
CU20170093A7 (es) | 2015-01-23 | 2017-09-06 | Novartis Ag | Conjugados de ácidos grasos y apelina sintética con mayor vida media |
ES2584534B1 (es) | 2015-03-27 | 2017-03-13 | Retinset, S.L. | Formulación tópica oftálmica de bosentan |
WO2018185516A1 (en) | 2017-04-05 | 2018-10-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy |
UY38072A (es) | 2018-02-07 | 2019-10-01 | Novartis Ag | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |
TWI833430B (zh) * | 2021-11-08 | 2024-02-21 | 大陸商正大天晴藥業集團股份有限公司 | 氮雜聯苯類化合物及其應用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1545944A1 (de) * | 1964-06-19 | 1969-12-11 | Hoffmann La Roche | Verfahren zur Herstellung von neuen Sulfonamiden der Pyrimidinreihe |
AU6623690A (en) * | 1990-10-29 | 1992-05-26 | Ibrahim Raouf Shimi | Novel sulfamide derivatives, a method for obtaining them and their use as a drug |
-
1992
- 1992-01-31 RU SU925011139A patent/RU2086544C1/ru active Protection Beyond IP Right Term
- 1992-06-04 DK DK92109431T patent/DK0526708T3/da not_active Application Discontinuation
- 1992-06-04 SG SG1996004376A patent/SG54209A1/en unknown
- 1992-06-04 EP EP92109431A patent/EP0526708B1/de not_active Expired - Lifetime
- 1992-06-04 PT PT92109431T patent/PT526708E/pt unknown
- 1992-06-04 DE DE59209872T patent/DE59209872D1/de not_active Expired - Lifetime
- 1992-06-04 ES ES92109431T patent/ES2152222T4/es not_active Expired - Lifetime
- 1992-06-04 AT AT92109431T patent/ATE197044T1/de active
- 1992-06-04 DE DE10299047C patent/DE10299047I2/de active Active
- 1992-06-05 ZA ZA924126A patent/ZA924126B/xx unknown
- 1992-06-09 AU AU18121/92A patent/AU653604B2/en not_active Expired
- 1992-06-09 US US07/896,015 patent/US5292740A/en not_active Expired - Lifetime
- 1992-06-09 MX MX9202747A patent/MX9202747A/es active IP Right Grant
- 1992-06-09 NZ NZ243074A patent/NZ243074A/en not_active IP Right Cessation
- 1992-06-09 IL IL10213892A patent/IL102138A/en active Protection Beyond IP Right Term
- 1992-06-10 DZ DZ920066A patent/DZ1587A1/fr active
- 1992-06-10 JP JP4174993A patent/JPH0730042B2/ja not_active Expired - Fee Related
- 1992-06-10 HU HU9201930A patent/HU221203B1/hu active Protection Beyond IP Right Term
- 1992-06-11 RO RO92-0780A patent/RO111268B/ro unknown
- 1992-06-12 CA CA002071193A patent/CA2071193C/en not_active Expired - Lifetime
- 1992-06-12 NO NO922323A patent/NO303826B1/no not_active IP Right Cessation
- 1992-06-12 CZ CS921804A patent/CZ281434B6/cs not_active IP Right Cessation
- 1992-06-12 SK SK1804-92A patent/SK279006B6/sk not_active IP Right Cessation
- 1992-06-12 IS IS3877A patent/IS2054B/is unknown
- 1992-06-12 KR KR1019920010205A patent/KR100235507B1/ko not_active IP Right Cessation
- 1992-06-12 FI FI922746A patent/FI112216B/fi active Protection Beyond IP Right Term
- 1992-06-15 BR BR929202219A patent/BR9202219A/pt not_active Application Discontinuation
- 1992-07-01 IE IE192092A patent/IE921920A1/en active Protection Beyond IP Right Term
- 1992-11-18 TW TW081109235A patent/TW222625B/zh not_active IP Right Cessation
-
1994
- 1994-02-28 BG BG98607A patent/BG60831B2/bg unknown
- 1994-11-23 EE EE9400322A patent/EE03028B1/xx unknown
-
1995
- 1995-06-20 HU HU95P/P00261P patent/HU211683A9/hu unknown
-
2000
- 2000-12-28 GR GR20000402849T patent/GR3035162T3/el unknown
-
2001
- 2001-11-01 CY CY0100036A patent/CY2306B1/xx unknown
-
2002
- 2002-09-02 NL NL300097C patent/NL300097I1/nl unknown
- 2002-10-16 LU LU90976C patent/LU90976I2/fr unknown
- 2002-10-16 LU LU90975C patent/LU90975I2/fr unknown
- 2002-10-29 NO NO2002012C patent/NO2002012I2/no unknown
-
2004
- 2004-10-27 CY CY2004005C patent/CY2004005I2/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EE03028B1 (et) | Sulfoonamiidid, nende kasutamine, ravimid ja valmistamise meetod | |
ES2096673T3 (es) | Uso de sulfonamidas como medicamentos y nuevas sulfonamidas. | |
DK0479903T3 (da) | Substituerede imidazoler og deres anvendelse som angiotensin II hæmmere | |
DK300287D0 (da) | Kondenserede cycliske azepin-2-oner, og deres anvendelse som antihypertensive laegemidler | |
DE3780016D1 (de) | Pharmazeutisches praeparat mit 3'-desoxythymidin-2'-en(3'-desoxy-2',3'-didehydrothymidin) zur behandlung von patienten mit retroviralen infektionen. | |
DK131887A (da) | 1,2,3,4-tetrahydro-3-carbamoyl-2-thioxo/oxo-5-pyrimidencarboxylsyre-derivater og deres anvendelse som laegemidler | |
ATE75399T1 (de) | Therapeutikum zur behandlung von magengeschwueren. | |
MY108302A (en) | Novel sulfonamides | |
DK37787A (da) | 2,3-dioxabicyclooe3,3,0aaoctan-derivater og deres anvendelse som laegemidler | |
DK514786D0 (da) | 5-heterocyclyl-2,4-dialkyl-3h-1,2,4-triazol-3-thioner og tautomere og farmaceutisk acceptable salte deraf, deres fremstilling og anvendelsesom antidepressive midler | |
ATE56445T1 (de) | Pharmacologisch aktive propionylanilide. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
KB4A | Valid patent at the end of a year |
Effective date: 20021231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20031231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20041231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20051231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20061231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20071231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20081231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20091231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20101231 |
|
QB4A | Licence registered |
Free format text: UNLIMITED LICENSE Name of requester: ACTELION PHARMACEUTICALS LTD, CH |